This study has shown that the predictors associated with pCR to radiotherapy are based on contributions from the tumour microenvironment, notably stromal cells (TGFβ signalling) and immune response (CMS1, cytotoxic lymphocytes). The gene discussed is TGFB1; the disease is neoplasm.